The choice of adjuvant treatment for individuals with surgically excised cutaneous melanoma depends on multiple determinants, including tumor stage, BRAF mutation status, the probability of relapse, comorbid conditions and patient wishes. This evidence concerns the gene BRAF and neoplasm.